1,2-diaminonaphthalene dihydrochloride | 73692-58-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1,2-diaminonaphthalene dihydrochloride
• 英文别名: naphthalene-1,2-diyldiamine; dihydrochloride；Naphthalin-1,2-diyldiamin; Dihydrochlorid；Naphthalene-1,2-diamine hydrochloride；naphthalene-1,2-diamine;hydrochloride
• CAS: 73692-58-7
• 化学式: C₁₀H₁₀N₂*2ClH
• 分子量: 231.125
• InChiKey: CXLMAIVOCVJQRM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.43
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  52
• 氢给体数：
  3
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1,2-diaminonaphthalene dihydrochloride 在 盐酸 、 硫酸 、 硝酸 作用下， 反应 4.5h， 生成 6-nitro-3H-benzo[e]benzimidazole
  参考文献：
  名称：

  Abdel-Hay, F. I.; Anwar, M.; Farag, W. M., Polish Journal of Chemistry, 1981, vol. 55, # 4, p. 917 - 920

  摘要：

  DOI：

文献信息

• [EN] NON PSYCHOACTIVE CANNABINOIDS AND USES THEREOF<br/>[FR] CANNABINOÏDES NON PSYCHOACTIFS ET LEURS UTILISATIONS
  申请人：YISSUM RES DEV CO

  公开号：WO2012011112A1

  公开（公告）日：2012-01-26

  The present invention provides dihydro-CBD compounds of formula (I) and derivatives thereof, compositions comprising them and uses thereof in the manufacture of medicaments for the treatment of conditions, diseases, disorders or symptoms associated with inflammation.

  本发明提供了公式(I)的二氢-CBD化合物及其衍生物，包括它们的组成物和用途，用于制造治疗与炎症相关的疾病、疾病、障碍或症状的药物。
• Benzo[f]quinoxaline-2,3(1H,4H)-diones
  申请人：Novo Nordisk A/S

  公开号：US05026704A1

  公开（公告）日：1991-06-25

  Heterocyclic dihydroxyquinoxaline compounds having the formula ##STR1## wherein R.sup.1 is C.sub.1-12 -alkyl, which may optionally be substututed by hydroxy, formyl, carboxy, carboxylic esters, amides or amines, C.sub.3-8 -cycloalkyl, aryl, aralkyl; and wherein R.sup.6 is, hydrogen, halogen, CN, CF.sub.3, NO.sub.2, or OR', wherein R' is C.sub.1-4 -alkyl and R.sup.5, R.sup.7 and R.sup.8 is hydrogen, provided R.sup.6 is not CF.sub.3, OCH.sub.3, NO.sub.2, Cl or Br when R.sup.1 is CH.sub.3 ; or R.sup.6 and R.sup.7 independently are NO.sub.2, halogen, CN, CF.sub.3, or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.5 and R.sup.8 are each hydrogen; or R.sup.5 and R.sup.6 together form a further fused aromatic ring, which may be substituted with halogen, NO.sub.2, CN, CF.sub.3 or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.7 and R.sup.8 independently are hydrogen, halogen, CN, CF.sub.3, NO.sub.2 or OR', wherein R' is C.sub.1-4 - alkyl; or R.sup.7 and R.sup.8 together form a further fused aromatic ring, which may be substituted with halogen, NO.sub.2, CN, CF.sub.3 or OR', wherein R' is C.sub.1-4 -alkyl, and R.sup.5 and R.sup.6 independently are hydrogen, halogen, CN, CF.sub.3, NO.sub.2 or OR', wherein R' is C.sub.1-4 -alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物：##STR1## 其中R.sup.1是C.sub.1-12烷基，可以选择被羟基，甲酰基，羧基，羧酸酯，酰胺或胺取代，C.sub.3-8环烷基，芳基，芳基烷基；R.sup.6是氢，卤素，CN，CF.sub.3，NO.sub.2或OR'，其中R'是C.sub.1-4烷基，R.sup.5，R.sup.7和R.sup.8是氢，只要当R.sup.1是CH.sub.3时，R.sup.6不是CF.sub.3，OCH.sub.3，NO.sub.2，Cl或Br；或者R.sup.6和R.sup.7分别是NO.sub.2，卤素，CN，CF.sub.3或OR'，其中R'是C.sub.1-4烷基，而R.sup.5和R.sup.8是氢；或者R.sup.5和R.sup.6一起形成另一个进一步融合的芳香环，其中可以用卤素，NO.sub.2，CN，CF.sub.3或OR'取代，其中R'是C.sub.1-4烷基，而R.sup.7和R.sup.8分别是氢，卤素，CN，CF.sub.3，NO.sub.2或OR'，其中R'是C.sub.1-4烷基；或者R.sup.7和R.sup.8一起形成另一个进一步融合的芳香环，其中可以用卤素，NO.sub.2，CN，CF.sub.3或OR'取代，其中R'是C.sub.1-4烷基，而R.sup.5和R.sup.6分别是氢，卤素，CN，CF.sub.3，NO.sub.2或OR'，其中R'是C.sub.1-4烷基。本发明还涉及制备这些化合物的方法，其制药组合物以及它们的用途。这些化合物在治疗兴奋性神经递质引起的症状方面是有用的，特别是在治疗神经精神病方面。
• Quinoxaline compounds and their preparation and use
  申请人：NOVO NORDISK A/S

  公开号：EP0315959A2

  公开（公告）日：1989-05-17

  Heterocyclic dihydroxyquinoxaline compounds having the formula wherein R¹ is C₁₋₁₂-alkyl, which may obtionally be substituted by hydroxy, formyl, carboxy, carboxylic esters, amides or ami­nes, C₃₋₈-cycloalkyl, aryl, aralkyl; and wherein R⁶ is, hy­drogen, halogen, CN, CF₃, NO₂, or OR′, wherein R′ is C₁₋₄-­alkyl and R⁵, R⁷ and R⁸ is hydrogen, provided R⁶ is not CF₃, OCH₃, NO₂, CL or Br when R¹ is CH₃; or R⁶ and R⁷ independently are NO₂, halogen, CN, CF₃, or OR′, wherein R′ is C₁₋₄-alkyl, and R⁵ and R⁸ are each hydrogen; or R⁵ and R⁶ together form a further fused aromatic ring, which may be substituted with halogen, NO₂, CN, CF₃ or OR′, wherein R′ is C₁₋₄-alkyl, and R⁷ and R⁸ independently are hydrogen, halogen, CN, CF₃, NO₂ or OR′ wherein R′ is C₁₋₄-alkyl; or R⁷ and R⁸ together form a further fused aromatic ring, which may be substituted with halogen, NO₂, CN, CF₃ or OR′, wherein R′ is C₁₋₄-alkyl, and R⁵ and R⁶ independently are hydrogen, halogen, CN, CF₃, NO₂ or OR′, wherein R′ is C₁₋₄-alkyl. The invention also relates to a method of preparing the compounds, pharmaceutical compositions thereof, and their use. The compounds are useful in the treatment of indications caused by hyperactivity of the excitatory neurotransmitters, particularly the quisqualate receptors, and especially as neuroleptics.

  具有以下式子的杂环二羟基喹喔啉化合物 其中 R¹ 是 C₁₋₁₂-烷基，可被羟基、甲酰基、羧基、羧酸酯、酰胺或胺、C₃₋₈-环烷基、芳基、芳烷基取代；其中 R⁶ 是氢、卤素、CN、CF₃、NO₂ 或 OR′，其中 R′ 是 C₁₋₄-烷基和 R⁵、R⁷ 和 R⁸ 是氢，条件是 R⁶ 不是 CF₃、OCH₃、NO₂、CL 或 Br（当 R¹ 是 CH₃ 时）；或 R⁶ 和 R⁷ 独立地为 NO₂、卤素、CN、CF₃ 或 OR′，其中 R′为 C₁₋₄-烷基，且 R⁵ 和 R⁸ 均为氢；或 R⁵ 和 R⁶ 共同形成另一个可被卤素、NO₂、CN、CF₃ 或 OR′取代的融合芳环、其中 R′为 C₁₄-烷基，且 R⁷ 和 R⁸ 独立地为氢、卤素、CN、CF₃、NO₂ 或 OR′，其中 R′为 C₁₄-烷基；或 R⁷ 和 R⁸ 共同形成另一个可被卤素、NO₂、CN、CF₃ 或 OR′取代的融合芳环、其中 R′为 C₁₋₄-烷基，且 R⁵ 和 R⁶ 独立地为氢、卤素、CN、CF₃、NO₂ 或 OR′，其中 R′为 C₁₋₄-烷基。 本发明还涉及化合物的制备方法、其药物组合物及其用途。 本发明的化合物可用于治疗兴奋性神经递质，特别是喹乙醇受体亢进引起的适应症，尤其可用作神经抑制剂。
• Benzimidazole useful in the treatment of central nervous system disorders
  申请人：NEUROSEARCH A/S

  公开号：EP0616807A1

  公开（公告）日：1994-09-28

  Compounds having the formula: or a pharmaceutically acceptable salt thereof wherein    R³ is are useful for the treatment of various central nervous system disorders such as epilepsy and other convulsive disorders, anxiety, sleep disorders and memory disorders.

  具有以下式子的化合物 或其药学上可接受的盐 其中 R³ 是 可用于治疗各种中枢神经系统疾病，如癫痫和其他抽搐性疾病、焦虑症、睡眠障碍和记忆障碍。
• Cyclohexenyl compounds, compositions comprising them and uses thereof
  申请人：Yissum Research Development Company of The Hebrew University of Jerusalem Ltd.

  公开号：US10239848B2

  公开（公告）日：2019-03-26

  Compositions that include certain phenyl substituted cyclohexenyl compounds are administered to a subject in a method for treating obesity or an associated disease or disorder or in a method of reducing food consumption or body weight.

  在治疗肥胖症或相关疾病或紊乱的方法中，或在减少食量或体重的方法中，可向受试者施用包括某些苯基取代的环己烯化合物的组合物。